Miltenyi Biomedicine GmbH
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Non Hodgkin Lymphoma
Long-term Follow-Up
This is a non-therapeutic study design. After successful screening, subjects will be monitored for potential gene therapy-related adverse events for up to 15 years post MB-CART2019.1 infusion. Subjects will be assessed yearly for the occurrence of delayed adverse events (AEs), monitored for replication competent lentivirus (RCL) and assessed for long term efficacy as well as CAR-T persistence.
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 150 participants |
| Official Title : | A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a United States Miltenyi Biomedicine-Sponsored Clinical Study |
| Actual Study Start Date : | 2024-05-15 |
| Estimated Primary Completion Date : | 2039-12-01 |
| Estimated Study Completion Date : | 2039-12-01 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Stanford University
Stanford, California, United States, 94305
RECRUITING
Yale University
New Haven, Connecticut, United States, 06520
NOT YET RECRUITING
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States, 21201
RECRUITING
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
RECRUITING
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226